Berahyaluronidase alfa

Preclinical

Berahyaluronidase alfa is one of 46 therapeutic programs targeting Osteoarthritis, Knee. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Osteoarthritis, KneeNot yet recruiting

Osteoarthritis, KneePreclinical

Not yet recruiting

Competition

Competitive Landscape

47 competitors in Osteoarthritis, Knee

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Approved

1 2

Voltaren

Cymbalta

Marinol

Medrol

Colcrys

Calciferol

Aleve

Plaquenil

Cyklokapron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalNot yet recruiting

Osteoarthritis, Knee

NCT07705165

Clinical

Trials by Indication[1]

Osteoarthritis, Knee1 trial

A Randomized, Split Body, Evaluator-blinded, Trial on the Effect of Tergase Injection (Berahyaluronidase Alfa) on Reducing Edema After Both Total Knee Arthroplasty

Not yet recruiting·MMan Soo Kim·Preclinical·NCT07705165·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Berahyaluronidase alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Berahyaluronidase alfa. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Man Soo Kim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMan Soo Kim

Berahyaluronidase alfa

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Osteoarthritis, Knee1 trial

References

Drug Info

Quick Facts

Related News